Logo image of SLS

SELLAS LIFE SCIENCES GROUP I (SLS) Stock Fundamental Analysis

NASDAQ:SLS - Nasdaq - US81642T2096 - Common Stock - Currency: USD

1.32  +0.01 (+0.76%)

Fundamental Rating

2

SLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While SLS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SLS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SLS has reported negative net income.
SLS had a negative operating cash flow in the past year.
In the past 5 years SLS always reported negative net income.
SLS had a negative operating cash flow in each of the past 5 years.
SLS Yearly Net Income VS EBIT VS OCF VS FCFSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

SLS's Return On Assets of -227.81% is on the low side compared to the rest of the industry. SLS is outperformed by 91.65% of its industry peers.
SLS has a Return On Equity of -1182.35%. This is amonst the worse of the industry: SLS underperforms 84.01% of its industry peers.
Industry RankSector Rank
ROA -227.81%
ROE -1182.35%
ROIC N/A
ROA(3y)-292.14%
ROA(5y)-216.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLS Yearly ROA, ROE, ROICSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLS Yearly Profit, Operating, Gross MarginsSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

SLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLS has more shares outstanding
SLS has more shares outstanding than it did 5 years ago.
SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLS Yearly Shares OutstandingSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SLS Yearly Total Debt VS Total AssetsSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

SLS has an Altman-Z score of -24.60. This is a bad value and indicates that SLS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -24.60, SLS is doing worse than 88.81% of the companies in the same industry.
There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.6
ROIC/WACCN/A
WACC9.56%
SLS Yearly LT Debt VS Equity VS FCFSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M

2.3 Liquidity

SLS has a Current Ratio of 1.02. This is a normal value and indicates that SLS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.02, SLS is not doing good in the industry: 88.63% of the companies in the same industry are doing better.
SLS has a Quick Ratio of 1.02. This is a normal value and indicates that SLS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.02, SLS is not doing good in the industry: 87.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
SLS Yearly Current Assets VS Current LiabilitesSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.19% over the past year.
SLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)55.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.08% on average per year.
SLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.94% yearly.
EPS Next Y60.17%
EPS Next 2Y28.96%
EPS Next 3Y18.19%
EPS Next 5Y23.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y8.11%
Revenue Next 5Y64.94%

3.3 Evolution

SLS Yearly Revenue VS EstimatesSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
SLS Yearly EPS VS EstimatesSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLS Price Earnings VS Forward Price EarningsSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLS Per share dataSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

SLS's earnings are expected to grow with 18.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.96%
EPS Next 3Y18.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (2/21/2025, 11:30:59 AM)

1.32

+0.01 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners9.54%
Inst Owner Change26.27%
Ins Owners0.16%
Ins Owner Change52.24%
Market Cap95.81M
Analysts82.86
Price Target5.95 (350.76%)
Short Float %13.71%
Short Ratio3.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.98%
Min EPS beat(2)-29.95%
Max EPS beat(2)21.99%
EPS beat(4)1
Avg EPS beat(4)-2524.49%
Min EPS beat(4)-8900.9%
Max EPS beat(4)21.99%
EPS beat(8)3
Avg EPS beat(8)-1270.51%
EPS beat(12)3
Avg EPS beat(12)-864.45%
EPS beat(16)5
Avg EPS beat(16)-648.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 32.89
P/tB 95.9
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS0.04
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -227.81%
ROE -1182.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-292.14%
ROA(5y)-216.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z -24.6
F-Score3
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
EPS Next Y60.17%
EPS Next 2Y28.96%
EPS Next 3Y18.19%
EPS Next 5Y23.08%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y8.11%
Revenue Next 5Y64.94%
EBIT growth 1Y5.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.37%
OCF growth 3YN/A
OCF growth 5YN/A